Placebo of ILT-101

DRUG2 trials

Sponsors

Assistance Publique Hopitaux De Paris

Conditions

Autism Spectrum disorder ASDPatient with newly diagnosed (≤ 3 months) type 1 diabetes stage 3

Phase 2

DFIL2-REP - Study of the clinical and biological response to repeated administration of low-dose interleukin-2 in patients with type 1 diabetes who have retained residual insulin secretion

RecruitingCTIS2024-514043-29-00

Assistance Publique Hopitaux De ParisPatient with newly diagnosed (≤ 3 months) type 1 diabetes stage 3

Start: 2022-09-21Target: 24Updated: 2025-07-25

ALaDIN - Use of low doses of interleukin-2 in autism spectrum disorders

Not yet recruitingCTIS2025-522841-23-00

Assistance Publique Hopitaux De ParisAutism Spectrum disorder ASD

Target: 22Updated: 2025-11-17